10-KPeriod: FY2011

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2011

Filed February 28, 2012For Securities:MRK

Summary

Merck & Co., Inc. reported strong sales growth of 4% to $48.0 billion for the fiscal year ended December 31, 2011, driven by key products like Januvia, Janumet, and Singulair, along with contributions from their Animal Health division and the launch of Victrelis. The company continued its strategic focus on accelerating revenue growth and cost efficiencies through its Merger Restructuring Program, which is on track to deliver substantial savings. Despite facing patent expirations for some products and the ongoing impact of healthcare reforms and European austerity measures, Merck demonstrated resilience. The company also advanced its research and development pipeline, with several new drug candidates under regulatory review and in late-stage development, signaling a commitment to future growth.

Financial Highlights

51 data points
Beta

Revenue

$48.05B

64.9% Gross Margin

Net Income

$6.27B

13.1% Net Margin

EPS (Diluted)

$2.02

Total Assets

$105.13B

Cash & Equivalents

$13.53B

Free Cash Flow

$12.38B

Financial Statements
Beta
Revenue$48.05B
Cost of Revenue$16.87B
Gross Profit$31.18B
R&D Expenses$8.47B
SG&A Expenses$13.73B
Interest Expense$695.00M
Net Income$6.27B
EPS (Basic)$2.04
EPS (Diluted)$2.02
Shares Outstanding (Basic)3.07B
Shares Outstanding (Diluted)3.09B

Key Highlights

  • 1Merck reported a 4% increase in worldwide sales, reaching $48.0 billion in 2011, primarily driven by strong performance in diabetes treatments (Januvia, Janumet), Singulair, and Gardasil.
  • 2The company continued its global restructuring program aimed at optimizing costs, having realized approximately $2.9 billion in annual net cost savings since the merger and expecting further savings.
  • 3Merck's R&D pipeline showed progress with 19 drug candidates in Phase III development, and plans to file for approval of five major products between 2012 and 2013.
  • 4Healthcare reform in the U.S. impacted revenues through increased Medicaid rebates and the Medicare Part D coverage gap discount, totaling approximately $329 million.
  • 5European austerity measures and pricing actions negatively affected sales in the EU, a trend Merck anticipates will continue.
  • 6The company announced a quarterly dividend increase to $0.42 per share, reflecting confidence in its financial position.
  • 7Key products like Singulair and Maxalt are nearing patent expiration, with significant sales declines expected post-expiration, highlighting the importance of the R&D pipeline.

Frequently Asked Questions

Merck reported a 4% increase in worldwide sales, reaching $48.0 billion in 2011, driven by strong performance in several key pharmaceutical and vaccine products. Earnings per share were $2.02, which included impacts from acquisition-related costs, restructuring, and other charges.

Growth drivers included strong performance from diabetes treatments Januvia and Janumet, the respiratory medicine Singulair, the HPV vaccine Gardasil, and the HIV treatment Isentress. Additionally, the Animal Health segment and the launch of Victrelis for hepatitis C contributed to the revenue increase.

Key risks include the upcoming patent expirations for major products like Singulair and Maxalt, which are expected to lead to significant sales declines. Other challenges include pricing pressures globally, increased competition from generics, the impact of U.S. healthcare reform, European austerity measures, and ongoing litigation, particularly related to Vioxx.

Merck is actively managing its cost structure through its Merger Restructuring Program, aiming for substantial annual cost savings. Future growth is being driven by advancements in its R&D pipeline, with numerous drug candidates in late-stage development and strategic acquisitions, such as Inspire Pharmaceuticals.